Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· September 30, 2026
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
View original at finance.yahoo.comModerna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? Both Moderna MRNA and BioNTech BNTX are leading biotechs at the forefront of messenger RNA (mRNA) technology…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Moderna and Merck plan to present detailed results at ESMO on Oct. 24 and engage with regulators regarding potential filings.
60% confidenceModerna and Merck are advancing intismeran across nine phase II and phase III studies spanning multiple tumor types, including NSCLC, bladder cancer and renal cell carcinoma.
60% confidenceThe intismeran plus Keytruda late-stage study in resected high-risk (Stage IIB-IV) melanoma met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.
60% confidence
Cited in these Via News reports
- Cancer's two big bets: a personalised vaccine that held melanoma at bay, and AI that designs the drugs. Here is what is verified and what is not →
- Oncology's Next Wave Arrives on a Calendar: A Cancer Vaccine Readout on Oct. 24, an FDA Decision on Nov. 14 →
- Oncology's Q4 Decision Window: Three Dated Catalysts, One Already Delivered, and a Sector Splitting Between Cash-Rich and Cash-Careful →